Cargando…

Renal-clearable hyaluronic acid functionalized NaGdF(4) nanodots with enhanced tumor accumulation

Integration of high tumor-targeting capacity, controlling in vivo transport and low normal tissue retention into one engineered nanoparticle is a critical issue for future clinically translatable anti-cancer nanomedicines. Herein, hyaluronic acid functionalized 3.8 nm NaGdF(4) nanodots (named NaGdF(...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yining, Ding, Lei, Liu, Lin, Abualrejal, Murad M. A., Chen, Hongda, Wang, Zhenxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Royal Society of Chemistry 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9051644/
https://www.ncbi.nlm.nih.gov/pubmed/35492986
http://dx.doi.org/10.1039/c9ra08974h
Descripción
Sumario:Integration of high tumor-targeting capacity, controlling in vivo transport and low normal tissue retention into one engineered nanoparticle is a critical issue for future clinically translatable anti-cancer nanomedicines. Herein, hyaluronic acid functionalized 3.8 nm NaGdF(4) nanodots (named NaGdF(4) ND@HAs) have been prepared through conjugation of tryptone capped NaGdF(4) nanodots (NaGdF(4) ND@tryptone) with hyaluronic acid (HA, a naturally occurring glycosaminoglycan), which can recognize the overexpressed CD44 on cancer cell membranes. The as-prepared NaGdF(4) ND@HAs have good paramagnetic properties (longitudinal relaxivity (r(1)) = 7.57 × 10(−3) M S(−1)) and low cytotoxicity. The in vivo experimental results demonstrate that the NaGdF(4) ND@HAs can not only efficiently accumulate in mouse-bearing MDA-MB-231 tumors (ca. 5.3% injection dosage (ID) g(−1) at 2 h post-injection), but also have an excellent renal clearance efficiency (ca. 75% injection dosage (ID) at 24 h post-injection). The as-prepared NaGdF(4) ND@HAs have good paramagnetic properties with enhanced tumor-targeting capacity, which provides a useful strategy for the preparation of renal clearable magnetic resonance imaging (MRI) contrast agents for tumors.